stoxline Quote Chart Rank Option Currency Glossary
Allarity Therapeutics, Inc. (ALLR)
0.5612  0.073 (15%)    12-08 16:00
Open: 0.559
High: 0.63
Volume: 4,930,728
Pre. Close: 0.488
Low: 0.4619
Market Cap: 2(M)
Technical analysis
2023-12-08 4:41:32 PM
Short term     
Mid term     
Targets 6-month :  0.97 1-year :  1.28
Resists First :  0.83 Second :  1.1
Pivot price 0.53
Supports First :  0.4 Second :  0.33
MAs MA(5) :  0.54 MA(20) :  0.51
MA(100) :  1.15 MA(250) :  92.74
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  13.2 D(3) :  17.3
RSI RSI(14): 50.2
52-week High :  1890 Low :  0.4
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ALLR ] has closed below upper band by 28.6%. Bollinger Bands are 82% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 165 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.63 - 0.63 0.63 - 0.64
Low: 0.46 - 0.46 0.46 - 0.46
Close: 0.56 - 0.56 0.56 - 0.57
Company Description

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Headline News

Wed, 06 Dec 2023
Can Allarity Therapeutics Inc (ALLR) Stock Rise to the Top of Healthcare Sector Wednesday? - InvestorsObserver

Tue, 05 Dec 2023
Dow Falls 100 Points; ISM Services PMI Increases In November - Allarity Therapeutics (NASDAQ:ALLR), Clear - Benzinga

Tue, 05 Dec 2023
Why Is Allarity Therapeutics (ALLR) Stock Up 42% Today? - InvestorPlace

Tue, 05 Dec 2023
Allarity's Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected ... - Yahoo Finance

Fri, 01 Dec 2023
Where Will Allarity Therapeutics Inc (ALLR) Stock Go Next After It Has Gained 9.62% in a Week? - InvestorsObserver

Mon, 02 Oct 2023
Allarity Therapeutics to Present at Biomarkers Europe 2023 - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out -7 (M)
Shares Float 0 (M)
Held by Insiders 4.56e+006 (%)
Held by Institutions 3.93e+006 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.541e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 625.42
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -60.3 %
Return on Equity (ttm) -20 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 189810
Forward Dividend 288190
Dividend Yield 33822200%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android